Kornimate/medical-research-clean huggingface dataset:
social anxiety disorder study of paroxetine

Conditions: Social Phobia

Summary: this study is designed to evaluate the efficacy and safety in social anxiety disorder (sad).


Eligibility criteria:
inclusion criteria: * diagnosis of social anxiety disorder (sad) (300.23 social phobia/social anxiety disorder) according to dsm-iv-tr criteria. * must give a written informed consent. but if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent. * patients have a minimum score of 60 on the lsas total score. exclusion criteria: * patients primarily diagnosed with a disorder that is categorized into axis i excluding sad by dsm-iv-tr (e.g. major depression, dysthymic disorder, specific phobia (simple phobia) , obsessive compulsive disorder, panic disorder) within 24weeks before week -2. * patients with a history or complication of schizophrenia and bipolar disorder * patients with a complication of body dysmorphic disorder. * patients with evidence of substance abuse (alcohol or drugs) * substance dependence by dsm-iv-tr criteria within 24 weeks before week -2. * patients who started psychotherapy and cognitive-behavioural therapy within 24 weeks before week-2, except for supportive psychotherapy. * patients receiving electro-convulsive therapy (ect) within 12 weeks before week -2. * patients being pregnant, lactating or are of childbearing potential and are likely to become pregnant. * patients with 3 or more points of ham-d item no. 3, or who are likely to attempt suicide. * patients with a history or complication of cancer or malignant tumor. * patients receiving mao inhibitors (fp®) within 14 days before expected week 0 visit date.

Keywords: anxiety sad social disorder
ventaprost in subjects with covid-19 requiring mechanical ventilation

Conditions: COVID-19

Summary: the purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with covid-19 who are on mechanical ventilation.

this study will evaluate the potential therapeutic benefit of ventaprost in treating patients with covid-19 at risk for respiratory and/ or cardiac/circulatory failure. this is a double-blind, placebo controlled study of ventaprost in 10 confirmed covid-19 patients compared to 10- covid-19 placebo patients to assess the efficacy and safety of ventaprost given over 10 days at varying doses.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 positive by rt-pcr test * patients who require invasive mechanical ventilation. * consent or professional consent obtained exclusion criteria: * patients on ecmo support. * patients receiving another inhalation research medication or inhaled nitric oxide. * not expected to survive for 48 hours. * allergy to epoprostenol and its diluent

Keywords: covid-19 ards
stress response and neurodevelopmental outcome after cardiac surgery utilizing cpb in children: a prospective, double blinded and randomized study

Conditions: Congenital Heart Disease

Summary: the overall goal of this project is to determine the role of anesthetic management in children undergoing cardiac surgery utilizing cpb in the setting of fast tracking and early extubation. an ideal anesthetic technique would ensure abolishing or diminishing stress response as would be evident by the stress markers levels and the level of two cerebral injury biomarkers (s 100 b and nse). this should translate to better immediate postoperative outcome and hopefully improve both the short and the long term neurodevelopmental outcome in these children. the project is prospective, randomized and blinded study. the first and second aim of the study should be conducted over 2 year period. our long term aim will be concluded when these children reach the school age.


Eligibility criteria:
inclusion criteria: * patients with the following diagnosis: 1. asd 2. vsd 3. avsd 4. tof 5. biventricular repair with left to right shunt. exclusion criteria: * patients with the diagnosis of avsd and pulmonary hypertension * patients less than 1 year and require any of the following repairs: 1. hlhs 2. aortic arch reconstruction 3. arterial switch 4. tof with pulmonary atresia
argentinian prospective registry of patients with lupus

Conditions: SLE

Summary: in latin america, information about patients with systemic lupus erythematosus (sle) is limited. multicenter studies are needed to obtain "real world data '' and to carry out longer follow-ups. the purpose of this project is to design a cohort of argentinian patients with sle to describe "our real setting" and to identify possible limitations in access to specialized consultations and treatments.

a longitudinal and multicenter cohort study of patients with systemic lupus erythematosus (sle) is planned, with a follow-up of for 5 years. the data will be obtained from the clinical history of each patient. the responsible for data collection will always be a physician with experience in the management of patients with sle and who has received training for data loading. the data will be collected through the an electronic case report form (ecrf) specially designed for this record and which in turn will facilitate the control of the data and the generation of inquiries to the researchers. study variables baseline visit: sociodemographic data classification criteria american college of rheumatology (acr 1982/1997), systemic lupus international collaborating clinics (slicc 2012) and/or european league against rheumatism / american college of rheumatology (eular / acr 2019) history of sle access to specialized care current clinical manifestations activity and damage scores current treatments patient-reported outcomes (pros): self-reported quality of life questionnaires eq-5r; physician global assessment (pga) and the patient comorbidities vaccination habits obstetric history associated antiphospholipid syndrome hospitalizations for adverse event, infections, or lupus activity annual clinical follow-up visits clinical follow-up of the patient changes in clinical manifestations changes in treatments use of health services; hospitalizations; high cost treatments activity and damage scores pros annual global and sle-related mortality study endpoints * number of patients who achieved complete clinical remission or low disease activity status (ldas) * impact on the quality of life and working life measured by pros and pga * mortality annual and global during the follow up period * change in disease activity and damage scores * health care resources used reported as number of hospitalizations, emergency visits and need of high cost treatment * accessibility to high cost treatment * survival of mains drugs reported as time between the first dose and the last dose * safety of mains drugs assessed as reason for their discontinuation

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * classified as sle (according to the 1982/1997 american college of rheumatology criteria and/or systemic lupus international collaborating clinics criteria for sle) * less than 5 years from meeting sle criteria * informed consent signature exclusion criteria: * diagnosis of other systemic autoimmune diseases or overlap syndromes * patients who have been transferred to other centers
use of continuous glucose monitoring system with intensive feedback in adolescents with poorly controlled type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to determine that continuous glucose monitoring systems (cgms) with intensive real time feedback about diabetes management from medical staff to the patient will affect motivation and/or behavior, in adolescents with poorly controlled type 1 diabetes. the investigators hypothesize that short-term cgms use with feedback (and/or lack thereof) and patients' sense of self-efficacy will influence their stage of change and potentially glucose levels.

sixty adolescents, ages 13-19 years, with type 1 diabetes and an hba1c \> = 8 % who are also naive to cgms use will be recruited from the diabetes outpatient population followed at bellevue hospital, lutheran hospital, woodhull hospital, and the nyu fink pediatric ambulatory care center. forty subjects will be randomly assigned to the cgms group and 20 subjects will be assigned to the control group.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * hba1c \> = 8 % * naive to cgms use exclusion criteria: * patients with developmental delay * patients who do not use a glucose meter to test capillary blood glucose level * patients without access to a telephone will be excluded.

Keywords: type 1 diabetes adolescents glucose monitoring
induction of mild hypothermia following out-of-hospital cardiac arrest

Conditions: Out-of-hospital Cardiac Arrest

Summary: the overall goal of this study is to determine whether initiating hypothermia in cardiac arrest patients as soon as possible in the field results in a greater proportion of patients who survive to hospital discharge compared to standard prehospital/field care.

in this study we will randomize 1,200 cardiac arrest patients who have return of spontaneous circulation (rosc) to hypothermia with rapid infusion of 2 liters of 4oc normal saline iv solution over 20 to 30 minutes, iv sedation and muscle paralysis or to standard of care following rosc. the primary objective of this study will be to determine whether induction of mild hypothermia using an infusion of cold normal saline will improve the proportion of patients who survive and are discharged awake from the hospital. hypothesis: in cardiac arrest patients who achieve rosc in the field, initiation of hypothermia by infusion of cold normal saline will result in a greater proportion of cardiac arrest patients discharged awake from the hospital compared to standard care.

Eligibility criteria:
inclusion criteria: * successful resuscitation from out-of-hospital cardiac arrest by paramedics, defined by having a palpable pulse exclusion criteria: * traumatic cause for cardiac arrest

Keywords: cardiac arrest mild hypothermia
throid dysfunction in liver failure and its eddects upon outcome

Conditions: Hepatic Encephalopathy; Hepatic Impairment; Hypothyroidism; Hepatic Failure

Summary: liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (t4) to triiodothyronine (t3) by type 1 deiodinase.

in clinical terms, cirrhosis is described as are either "compensated" or "decompensated." decompensation means cirrhosis complicated by one or more of the following features: jaundice, ascites, hepatic encephalopathy (he), or bleeding varices. ascites is the usual first sign. hepatorenal syndrome, hyponatremia, and spontaneous bacterial peritonitis are also features of decompensation, but in these patients, ascites invariably occurs first. compensated cirrhotic patients have none of these features. the liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (t4) to t3 by type 1 deiodinase. t4 and t3 regulate the basal metabolic rate of all cells, including hepatocytes, and thereby modulate hepatic function. the liver metabolizes the ths and regulates their systemic endocrine effects. thyroid diseases may perturb liver function; liver disease modulates thyroid hormone metabolism; and a variety of systemic diseases affect both the organs.

Eligibility criteria:
inclusion criteria: - hepatic fauiure patients exclusion criteria: * hypethyroid patients

Keywords: hepatic failure hypothyroidism
a study to determine if bhv-8000 is effective, safe and tolerable as a treatment for adults living with early parkinson's disease

Conditions: Parkinson Disease

Summary: a study to determine if bhv-8000 is efficacious, safe and tolerable in adults diagnosed with early parkinson's disease.


Eligibility criteria:
key inclusion criteria: * male or female participants 40 to 85 years of age, inclusive, at the time of informed consent. * meet the diagnostic criteria for "probable pd" as assessed on the movement disorder society (mds) clinical diagnostic criteria for pd as assessed by the investigator. * have a clinician-documented diagnosis of idiopathic pd with an onset within 2 years of the screening visit key exclusion criteria: * medical history indicating a parkinsonian syndrome other than idiopathic pd, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced parkinsonism, essential tremor, or primary dystonia. * diagnosis of clinically significant central nervous system (cns) disease other than pd. * participants who are current smokers (defined as smoking \[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\] within 6 months prior to the baseline visit). * treatment with pd medication(s) for a total of more than 28 days or treatment with any pd medication within 90 days of the baseline visit. * any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.

Keywords: early parkinson's disease parkinson's disease early onset parkinson's disease treatment naiive early parkinson's disease
retrospective longitudinal study of gestational weight gain among chinese pregnant women

Conditions: Gestational Weight Gain

Summary: the purpose of this study is to investigate the reference ranges and rates of gestational weight gain among chinese pregnant women, and to analyze the correlation between gestational weight gain and adverse outcomes.


Eligibility criteria:
inclusion criteria: 1. deliveries between january 2013 and december 2014; 2. gestational age between 37 weeks or older and less than 42 weeks; 3. registration with care documents at the first prenatal visit prior to the 15th gestational week; 4. had at least five follow-up visits until delivery. exclusion criteria: none

Keywords: gestational weight gain chinese pregnant women retrospective longitudinal study china iom guideline adverse outcome model
sarcopenia after bariatric surgery in older patients: a cohort study

Conditions: Overweight and Obesity; Bariatric Surgery; Aging; Sarcopenic Obesity

Summary: the retrospective cohort study will compare the prevalence of sarcopenia and associated factors between older patients who have undergone bariatric surgery and older patients with obesity without previous bariatric surgery.

the aim of the study is to compare the prevalence of sarcopenia and nutritional status between adults older than 65 years who have previously undergone bariatric surgery and patients with obesity but without previous bariatric surgery. current sarcopenia will be assessed during a cross-sectional assessment after surgery using the criteria from the european working group on sarcopenia in older people (ewgsop).

Eligibility criteria:
inclusion criteria: * signed informed consent * age 65 years or older * cohort 1 (exposed): previous bariatric surgery for obesity at least 1 one year ago * cohort 2 (unexposed): no previous weight loss surgery exclusion criteria: * current diagnosis of cancer * advanced organ failure, including chronic kidney disease stage 5, liver cirrhosis stage 3, intestinal failure, heart failure stage d, or chronic obstructive pulmonary disease stage 4. * immobility * neuromuscular degenerative conditions
evaluation of the effect on glucose control and safety of ac2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination

Conditions: Diabetes Mellitus, Type 2

Summary: this multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of ac2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes * treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination * bmi 25-45 kg/m\^2 * hba1c between 7.5 % and 12.0 %, inclusive exclusion criteria: * treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening * patients previously treated with ac2993 * patients presently treated with insulin

Keywords: exenatide exendin-4 diabetes amylin lilly
genomic brca and extensive ovarian cancer testing

Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Summary: this is a prospective observational french multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage iii to iv figo 2014). the objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

this is a prospective observational french multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage iii to iv figo 2014). the objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Eligibility criteria:
inclusion criteria: * patient older than 18 years. * patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage iii to iv figo 2014) * patient in first line therapy * available tumor sample fixed in formalin and included in paraffin (ffpe): * in pre-chemotherapy, insofar as possible * having a sufficient tumor surface, with a final cellularity of at least 20% * identification of a molecular genetics' cancer platform participant in great and an onco-geneticists team working with the investigator team * patient consenting her data to be collected and submitted through an automated processing * patient beneficiary from the french social security exclusion criteria: * patient with a mucinous ovarian carcinoma * patient pregnant or breastfeeding * patient under legal protection (guardianship or court order) or unable to consent
obinutuzumab versus rituximab for acute lymphoblastic leukemia/palg all7 "overall"

Conditions: CD20-positive Acute Lymphoblastic Leukemia

Summary: a multicenter, prospective, randomized and controlled study to compare the efficacy and safety of obinutuzumab and rituximab in adult all patients with cd20 expression.study population is 124 patients (62 in each study group).


Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. newly diagnosed acute lymphoblastic leukemia with cd20 expression on at least 20% of blasts. 3. signed written informed consent. 4. adequate contraception in case of women with child-bearing potential exclusion criteria: 1. lymphoblastic lymphoma with bone marrow blasts\<20%. 2. patients with a history of chronic myeloid leukemia or other myeloproliferative disease. 3. major surgery within 4 weeks before enrollment. 4. impaired cardiac function: ejection fraction \ 450 ms on baseline electrocardiogram. myocardial infarction within 6 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias). 5. active infection e.g. hepatitis b virus, hepatitis c virus, human immunodeficiency virus 6. other concurrent severe and/or uncontrolled medical conditions: patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease. 7. serum creatinine \> 2 times the upper normal limit of the laboratory, total bilirubin\> 2.5 upper normal limit unless related to acute lymphoblastic leukemia, aspartate aminotransferase or alanine aminotransferase \> 5 upper normal limit, unless related to acute lymphoblastic leukemia 8. intolerance to treatment with monoclonal antibody. 9. positive pregnancy test (beta human chorionic gonadotropin) for women of childbearing age. 10. inability to obtain written informed consent. 11. inability to comply with regular monitoring.
innovative approaches in diabetes care

Conditions: Diabetes Mellitus; Mobile Application; Dietary Assessment; M-health

Summary: it is estimated that 2.3 million taiwanese have diabetes and there is a 44% increased rate among young adults and adolescents. poor dietary habits and sedentary lifestyle are the major risk factors for type 2 diabetes. the growing availability of smartphones has boosted the development of new technologies that incorporate the use of digital food photography as health promotion and individualized nutrition care. digital health technology is also used to prevent and treat diabetes with good degree of successes in the short term but the long term effect remains unknown. the broad aim of this study is to evaluate the effectiveness of digital technology ehealth care for diabetic patients. a total of 300 diabetic patients will be recruited from diabetes shared care network and community care center in taiwan and follow up 12 months. a simple randomization by computer system will be used to randomly allocate subjects into 2 groups: control group and ehealth care. the control group (n=100) of diabetic patients will receive conventional health and nutrition education from state registered dietitian. the ehealth care group (n=200) of diabetic patients will receive a 10 mins of food portion size nutrition education using " 3d/ar metafood platform" and is required to record their consume meal by food image once a week using taiwan foodapp. patients in the ehealth group will receive instant feedback from the nutritionists or artificial intelligence (ai) for the information of glycemic index (gi) and glycemic load (gl), and educational video related to healthy eating or how to select gi/gl food. anthropometry, and baseline questionnaires will be collected at baseline. blood biochemistry (e.g. hba1c) and body weight will be collected at baseline, 3, 6, 9, and 12 months. the collected food image data will be used for ai training to identify the relationship between the patient's diet and blood glucose changes over time.


Eligibility criteria:
inclusion criteria: * ≧20 years old * pre-diabetes or diabetes * taiwan nationality or people who can speak chinese fluently * currently not pregnant or breastfeeding * available to use smartphone to take photos and record food exclusion criteria: * eating disorders